Altimmune, Inc. (NASDAQ:ALT) Receives Average Rating of "Hold" from Analysts

Key Points

• Altimmune, Inc. has received an average rating of "Hold" from eight research firms, with a 12-month price target of $17.40.
• Institutional investors own 78.05% of Altimmune's stock, with notable increases in holdings from firms like GAMMA Investing and BNP Paribas.
• The company reported earnings of ($0.27) per share for the last quarter, exceeding estimates, while having a negative net margin of 438,730.03%.

Shares of Altimmune, Inc. (NASDAQ:ALT - Get Free Report) have earned an average rating of "Hold" from the eight research firms that are covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 12-month price target among brokers that have issued a report on the stock in the last year is $17.40.

A number of equities analysts recently issued reports on ALT shares. B. Riley decreased their price objective on Altimmune from $20.00 to $18.00 and set a "buy" rating for the company in a report on Wednesday, August 13th. HC Wainwright reissued a "buy" rating and issued a $12.00 price target on shares of Altimmune in a research note on Wednesday, August 13th. Weiss Ratings reissued a "sell (d-)" rating on shares of Altimmune in a report on Wednesday. The Goldman Sachs Group raised shares of Altimmune to a "strong sell" rating in a report on Thursday, July 10th. Finally, William Blair reiterated a "market perform" rating on shares of Altimmune in a research report on Friday, June 27th.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently made changes to their positions in ALT. GAMMA Investing LLC raised its position in shares of Altimmune by 214.2% during the first quarter. GAMMA Investing LLC now owns 6,745 shares of the company's stock worth $34,000 after purchasing an additional 4,598 shares during the period. BNP Paribas Financial Markets boosted its position in shares of Altimmune by 108.5% in the 2nd quarter. BNP Paribas Financial Markets now owns 10,095 shares of the company's stock valued at $39,000 after purchasing an additional 5,253 shares during the period. Kingswood Wealth Advisors LLC purchased a new position in Altimmune in the 2nd quarter worth about $40,000. Prudential Financial Inc. acquired a new stake in Altimmune during the 2nd quarter worth about $43,000. Finally, Headland Capital LLC acquired a new stake in Altimmune during the 1st quarter worth about $50,000. 78.05% of the stock is currently owned by institutional investors.

Altimmune Price Performance

Shares of NASDAQ:ALT opened at $3.93 on Thursday. The company's fifty day moving average is $3.71 and its two-hundred day moving average is $4.64. The company has a debt-to-equity ratio of 0.09, a quick ratio of 20.44 and a current ratio of 20.44. Altimmune has a 1-year low of $2.90 and a 1-year high of $11.16. The stock has a market capitalization of $346.86 million, a price-to-earnings ratio of -3.33 and a beta of 0.07.

Altimmune (NASDAQ:ALT - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.32) by $0.05. Altimmune had a negative net margin of 438,730.03% and a negative return on equity of 62.63%. The company had revenue of $0.01 million during the quarter, compared to the consensus estimate of $0.00 million. Equities analysts anticipate that Altimmune will post -1.35 EPS for the current year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.